CGON•CG Oncology reported a 41.8% complete response rate at 24 months for cretostimogene in Phase 3 BOND-003 Cohort C. No grade 3 or higher treatment-related adverse events were reported.
In Cohort C, the complete response rate was 75.5% at any time and 46.4% at 12 months. Cohort P showed 80.4% high-grade event-free survival at nine months in patients with BCG-unresponsive papillary-only bladder cancer.
The company said manufacturing capacity is 40,000–50,000 vials annually, with a tenfold scale-up underway to support future indications.
